Suppressive effect of 1,4-anhydro-4-seleno-D-talitol (SeTal) on atopic dermatitis-like skin lesions in mice through regulation of inflammatory mediators
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Suppressive effect of 1,4-anhydro-4-seleno-D-talitol (SeTal) on atopic dermatitis-like skin lesions in mice through regulation of inflammatory mediators. / Voss, Guilherme T.; de Oliveira, Renata L.; Davies, Michael J.; Domingues, William B.; Campos, Vinicius F.; Soares, Mauro P.; Luchese, Cristiane; Schiesser, Carl H.; Wilhelm, Ethel A.
In: Journal of Trace Elements in Medicine and Biology, Vol. 67, 126795, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Suppressive effect of 1,4-anhydro-4-seleno-D-talitol (SeTal) on atopic dermatitis-like skin lesions in mice through regulation of inflammatory mediators
AU - Voss, Guilherme T.
AU - de Oliveira, Renata L.
AU - Davies, Michael J.
AU - Domingues, William B.
AU - Campos, Vinicius F.
AU - Soares, Mauro P.
AU - Luchese, Cristiane
AU - Schiesser, Carl H.
AU - Wilhelm, Ethel A.
PY - 2021
Y1 - 2021
N2 - Background: Atopic dermatitis (AD) is a multifactorial chronic inflammatory disease that affects similar to 20 % of children and 3% of adults globally and is generally treated by the topical application of steroidal drugs that have undesirable side-effects. The development of alternative therapies is therefore an important objective. The present study investigated the effects of topical treatment with a novel water-soluble selenium-containing carbohydrate derivative (4-anhydro-4-seleno-D-tatitol, SeTal) on the symptoms and inflammatory parameters in an AD mouse model.Methods: Mice were sensitized by applying 2,4-dinitrochlorobenzene (DNCB) to their dorsal skin on days 1-3, then further challenged on their ears and dorsal skin on days 14, 17, 20, 23, 26, and 29. SeTal (1 and 2%) or hydrocortisone (1%) was applied topically to the backs of the mice from days 14-29, and skin severity scores and scratching behavior determined on day 30. The mice were euthanized, and their ears and dorsal skin removed to quantify inflammatory parameters, edema, myeloperoxidase (MPO) activity, and AD-associated cytokines (tumor necrosis factor alpha (TNF-alpha), interleukins (IL)-18, and IL-33).Results: DNCB treatment induced skin lesions and increased the scratching behavior, ear edema, MPO activity (ear and dorsal skin), and cytokine levels in dorsal skin. Topical application of SeTal improved inflammatory markers (cytokine levels and MPO activity), cutaneous severity scores, and scratching behavior.Conclusion: The efficacy of SeTal was satisfactory in the analyzed parameters, showing similar or better results than hydrocortisone. SeTal appears to be therapeutically advantageous for the treatment and control of AD.
AB - Background: Atopic dermatitis (AD) is a multifactorial chronic inflammatory disease that affects similar to 20 % of children and 3% of adults globally and is generally treated by the topical application of steroidal drugs that have undesirable side-effects. The development of alternative therapies is therefore an important objective. The present study investigated the effects of topical treatment with a novel water-soluble selenium-containing carbohydrate derivative (4-anhydro-4-seleno-D-tatitol, SeTal) on the symptoms and inflammatory parameters in an AD mouse model.Methods: Mice were sensitized by applying 2,4-dinitrochlorobenzene (DNCB) to their dorsal skin on days 1-3, then further challenged on their ears and dorsal skin on days 14, 17, 20, 23, 26, and 29. SeTal (1 and 2%) or hydrocortisone (1%) was applied topically to the backs of the mice from days 14-29, and skin severity scores and scratching behavior determined on day 30. The mice were euthanized, and their ears and dorsal skin removed to quantify inflammatory parameters, edema, myeloperoxidase (MPO) activity, and AD-associated cytokines (tumor necrosis factor alpha (TNF-alpha), interleukins (IL)-18, and IL-33).Results: DNCB treatment induced skin lesions and increased the scratching behavior, ear edema, MPO activity (ear and dorsal skin), and cytokine levels in dorsal skin. Topical application of SeTal improved inflammatory markers (cytokine levels and MPO activity), cutaneous severity scores, and scratching behavior.Conclusion: The efficacy of SeTal was satisfactory in the analyzed parameters, showing similar or better results than hydrocortisone. SeTal appears to be therapeutically advantageous for the treatment and control of AD.
KW - Cytokine
KW - Selenium
KW - 4-Anhydro-4-seleno-D-talitol
KW - Inflammation
KW - Hydrocortisone
KW - QUALITY-OF-LIFE
KW - MANAGEMENT
KW - MYELOPEROXIDASE
KW - GUIDELINES
KW - CELLS
KW - IL-18
U2 - 10.1016/j.jtemb.2021.126795
DO - 10.1016/j.jtemb.2021.126795
M3 - Journal article
C2 - 34091240
VL - 67
JO - Journal of Trace Elements in Medicine and Biology
JF - Journal of Trace Elements in Medicine and Biology
SN - 0946-672X
M1 - 126795
ER -
ID: 274524528